 Home > Active Ingredient News > Urinary System > 2022 Evaluation of the efficacy of pembrolizumab in patients with advanced UC in East Asia| ESMO ASIA—post-hoc analysis of KEYNOTE-045/052 study

2022 Evaluation of the efficacy of pembrolizumab in patients with advanced UC in East Asia| ESMO ASIA—post-hoc analysis of KEYNOTE-045/052 study

 Last Update: 2023-01-01
 Source: Internet
 Author: User

Tags

1 3 5 trimethoxybenzene

4 way rack

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Hosted by the European Society of Medical Oncology, ESMO ASIA is the leading platform
in the Asia-Pacific region to discuss the latest data and breakthroughs in oncology.
The conference brings together the most experienced international experts to present and discuss the latest academic research and clinical progress, and provides important networking opportunities
for experts and scholars in the field of oncology.
ESMO ASIA 2022 was held
online + offline in Singapore from December 2-4.
Pembrolizumab has greatly changed the treatment pattern of urothelial cancer, but most of the blockbuster studies have been carried out in Europe and the United States, and some scholars have conducted retrospective analysis to evaluate the efficacy and safety
of pembrolizumab in patients with East Asian urothelial cancer.
Let's take a look
together.

Research background

The KEYNOTE-052 (phase II.
) and KEYNOTE-045 (phase III) studies explored the efficacy of pembrolizumab as a first-line treatment for advanced urothelial carcinoma (UC) and a second-line treatment for platinum-refractory patients who are not suitable for cisplatin, respectively, and the results showed that pembrolizumab showed durable antitumor activity and a controllable safety profile
.
To assess whether the efficacy of pembrolizumab in East Asian populations is consistent
with that of the general population.

Study design

The study included patients
in East Asia in the KEYNOTE-052 study and the KEYNOTE-045 study.
Patients in the KEYNOTE-052 study were randomized 1:1 to receive investigator-selected chemotherapy regimens (paclitaxel: 175 mg/m2 IV Q3, docetaxel 75 mg/m2 IV Q3, or vinofonin: 320 mg/^m2IV Q3) or pembrolizumab (200 mg, IV, Q3W for 2 years
).
。 All patients in the KEYNOTE-045 study were treated
with pembrolizumab (200 mg intravenously every 3 weeks for 2 years).
The investigators reported objective response rate (ORR), overall survival (OS), and safety data
that were independently reviewed by blinded (RECIST v1.
1 criteria).
Data are current to 1 October 2020 (KEYNOTE-045 study) and 26 September 2020 (KEYNOTE-052 study).

Figure 1 Study design

Study results

A total of KEYNOTE-045 studies were included (62 patients in the pembrolizumab group; 51 patients in the chemotherapy group) and 113 patients in the KEYNOTE-052 study (20 patients) were analyzed
.
The median follow-up time for patients enrolled in the KEYNOTE-045 study and KEYNOTE-052 study was 62.
4 (range 59.
2-68.
6) months and 57.
3 (range 51.
4-65.
2) months, respectively, with the rest of the baseline data shown in the figure below
.

Figure 2 Baseline data of enrolled patients

The patient's remission after treatment is shown in the figure below
.

Fig.
3 Remission of different groups of patients

FIG.
4 OS data of East Asian populations in the KEYNOTE-045 study

FIG.
5 OS data of East Asian populations in the KEYNOTE-052 study

In the KEYNOTE-045 study, the incidence of grade 3-5 treatment-related adverse events (TRAEs) in patients with pembrolizumab and chemotherapy was 16% (n=10) and 73% (n=37), respectively, with 1 patient dying from TRAEs
in each group.
In the KEYNOTE-052 study, a total of 2 (10%) patients developed TRAEs, of which 1 (5%) died
.

Conclusion of the study

The results of this post-hoc subgroup analysis showed that pembrolizumab exhibited consistent antitumor activity and safety in the KEYNOTE-045 study population in East Asian populations; Experimental results support pembrolizumab as a second-line regimen for patients with platinum-refractory advanced UC, but the small number of East Asian patients (20/370) in the KEYNOTE-052 study limits the generalizability
of its results.

The cover and accompanying pictures are from the official ESMO ASIA conference

Reference source:

https://asiacongress.
esmo.
org/esmo/asia2022/en-GB/presentation/551759

Edited by Rudolf Reviewed: Rudolf Executed by Gardenia

This platform is designed to deliver more medical information
to healthcare professionals.
The content published on this platform cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding medical information, this platform does not assume relevant responsibilities
.
The content published by this platform does not mean that it agrees with its description and views
.
If copyright issues are involved, please contact us and we will deal with
it as soon as possible.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.